The immuno-oncology therapy developer received funding from investors including Alexandria Real Estate Equities and strategic collaborator Celgene.
US-based small molecule drug developer Vividion Therapeutics closed an $82m series B round on Tuesday featuring pharmaceutical firm Celgene and life sciences and real estate investment trust Alexandria Real Estate Equities.
Investment firm Nextech Invest led the round, which included financial services firm Mirae Asset Capital, BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Altitude Life Science Ventures, Arch Venture Partners, Versant Ventures and Cardinal Partners.
Alexandria Real Estate Equities took part in the round through its venture capital arm,…
